FibroGen to Report Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015

Conference Call and Webcast Scheduled for 4:30 p.m. ET (1:30 p.m. PT)

SAN FRANCISCO--(BUSINESS WIRE)-- FibroGen, Inc. (NASDAQ: FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).

Audio Webcast

Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of four weeks.

Dial-In Information

Live (U.S. / Canada): (800) 708-4540

Live (International): (847) 619-6397

Confirmation number: 39222014

About FibroGen

FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia in chronic kidney disease patients who are dialysis-dependent, including hemodialysis and peritoneal dialysis, and not dialysis-dependent.

FibroGen, Inc.
Greg Mann, 415-978-1433
[email protected]

Source: FibroGen, Inc.

You May Also Be Interested In

• FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Prese
• FS Bancorp (FSBW) Tops Q1 EPS by 8c
• Goldman Sachs on Meta Platforms Inc. (META): 'We expect investors to have an initial negative reaction'